Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

17.69
-0.0700-0.39%
Post-market: 17.860.1700+0.96%18:15 EDT
Volume:2.13M
Turnover:37.65M
Market Cap:2.22B
PE:-9.85
High:18.09
Open:17.85
Low:17.46
Close:17.76
Loading ...

Australia’s TGA approves Apellis’ SYFOVRE for GA related to AMD

TIPRANKS
·
28 Jan

Apellis Receives Approval of Syfovre® (Pegcetacoplan) in Australia for Geographic Atrophy (Ga)

THOMSON REUTERS
·
28 Jan

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

GlobeNewswire
·
28 Jan

Wedbush Raises Price Target on Apellis Pharmaceuticals to $30 From $25, Keeps Neutral Rating

MT Newswires Live
·
23 Jan

Apellis Pharmaceuticals Price Target Maintained With a $26.00/Share by RBC Capital

Dow Jones
·
22 Jan

Apellis Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Jan

Apellis’ Syfovre can capitalize on competitor headwinds, says JPMorgan

TIPRANKS
·
14 Jan

Apellis Shares Rise After Reporting Preliminary Q4, Full-Year Product Sales Results

MT Newswires Live
·
14 Jan

Apellis Highlights Commercial Growth and Strategic Priorities at 43Rd Annual J.p. Morgan Healthcare Conference

THOMSON REUTERS
·
13 Jan

Press Release: Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

Dow Jones
·
13 Jan

Apellis appoints Keli Walbert to board of directors

TIPRANKS
·
10 Jan

Apellis Announces Keli Walbert to Join the Board of Directors

THOMSON REUTERS
·
10 Jan

Apellis Pharmaceuticals Inc - Board Expands to Seven Directors, Six Independent

THOMSON REUTERS
·
10 Jan

Press Release: Apellis Announces Keli Walbert to Join the Board of Directors

Dow Jones
·
10 Jan

Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)

TIPRANKS
·
10 Jan

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
08 Jan

RBC Raises Price Target on Apellis Pharmaceuticals to $26 From $24, Keeps Sector Perform Rating

MT Newswires Live
·
07 Jan